TABLE 3.
A list of selective clinical trials registered in ClinicalTrials.gov that enrolled and provided data specifically on aged (>65) patients with cancer
| Drug | Clinical trial-official title | PMID | Study id | Cancer/tria phase | Patients age Mean/ Median = X (range or SD) | (Review again) Total No. of patients | Serious AE: affected/total at risk (%) |
|---|---|---|---|---|---|---|---|
| Atezolizumab | A study of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer [IMvigor211] | 29268948 | NCT02302807 (2014–2019) | BLC/ Phase III | Mean = 65.9 | 459 | 192/459 (41.83%)a |
| Atezolizumab | A study of atezolizumab as first-line monotherapy for advanced or metastatic non-small cell lung cancer (B-F1RST) | — | NCT02848651 (2016–2020) | NSCLC/ Phase II | Mean = 68.7 | 152 | 81/152 (52.29%) |
| Atezolizumab | A study of atezolizumab in participants with programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic non-small cell lung cancer (BIRCH) | 28609226 | NCT02031458 (2014–2020) | NSCLC/ Phase II | Median = 66.8 | 138 | 47/138 (34.06%)b |
| Atezolizumab | A study of atezolizumab in participants with programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [FIR] | 29775807 | NCT01846416 (2013–2019) | NSCLC/ Phase II | Mean = 65.7 | 137 | 69/137 (50.36)c |
| Ipilimumab | A phase Ib study of Yervoy with sylatron for patients with unresectable stages IIIB/C/IV Melanoma | 28031816 | NCT01496807 (2011–2017) | Mel/Phase I | Median = 65 | 31 | 14/31 (45.16%) |
| Ipilimumab | Evaluation of circulating T cells and tumor infiltrating lymphocytes with specificities against tumor associated antigens during and after neoadjuvant chemotherapy and phased ipilimumab in non-small cell lung cancer | 29258674 | NCT01820754 (2013–2018) | NSCLC/ Phase II | Mean = 65.3 | 24 | 6/24 (25.00%) |
| Ipilimumab | A phase 2, randomized, double-blind study of ipilimumab administered at 3 mg/kg versus 10 mg/kg in adult subjects with metastatic chemotherapy-naïve castration resistant prostate cancer who are asymptomatic or minimally symptomatic | — | NCT02279862 (2014–2018) | PC/ Phase II | Mean = 66 | 51 | 21/51 (41.17%)c |
| Ipilimumab | Phase II study of combined ionizing radiation and ipilimumab in metastatic non-small cell lung cancer (NSCLC) | 30397353 | NCT02221739 (2014–2020) | NSCLC/ Phase II | Median = 68 | 39 | 19/39 (43.59%) |
| Ipilimumab | A phase I/II, open-label, dose-escalation study of MDX-010 administered every 3 weeks for four doses in patients with metastatic hormone-refractory prostate cancer | 23535954 | NCT00323882 (2006–2014) | PC/ Phase I & II | Mean = 65.7 | 71 | 35/71 (49.29%)c |
| Pembrolizumab | Randomized phase 2 trial of ACP-196 and pembrolizumab immunotherapy dual CHECKpoint inhibition in platinum resistant metastatic urothelial carcinoma (RAPID CHECK study) | — | NCT02351739 (2015–2019) | UC/ Phase II | Mean = 65.8 | 35 | 15/35 (42.86%)d |
| Pembrolizumab | Phase 2B single-site, open-label, nonrandomized study evaluating the efficacy of neoadjuvant pembrolizumab for unresectable stage III and unresectable stage IV melanoma | — | NCT02306850 (2014–2019) | MEL/ Phase II | Mean = 66.3 | 10 | 3/10 (30.00%) |
| Sipuleucel-T | A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loading with PA2024 (Provenge(R), APC8015) in men with metastatic androgen independent prostatic adenocarcinoma d treatment. y. lotherapy, arm 1 of study. study. | 20818862 | NCT00065442 (2003–2010) | PC/ Phase III | Median = 71.1 | 341 | 82/338 (24.26%)e |
a
Patients who received treatment.
b
Cohort-1 in this study.
c
All cohorts in study.
d
Pembrolizumab monotherapy, arm 1 of study.
e
Sipuleucel-T arm of study.